Skip to main content

Table 1 Demographics and clinical characteristics of 139 subjects

From: Collateral damage of using colistin in hospitalized patients on emergence of colistin-resistant Escherichia coli and Klebsiella pneumoniae colonization and infection

Variables Values
Female gender, n (%) 70 (50.4%)
Age (yrs), mean ± SD 67.2 ± 15.9
Comorbid conditions, n (%) 131 (94.2%)
 Diabetes mellitus 53 (38.1%)
 Cardiovascular diseases 41 (29.5%)
 Renal diseases 37 (26.6%)
 Cerebrovascular diseases 35 (25.2%)
 Solid malignancy 21 (15.1%)
 Chronic pulmonary diseases 20 (14.3%)
 Hematologic malignancy 16 (11.5%)
 Liver diseases 10 (7.2%)
 Organ transplantation 4 (2.9%)
 HIV infection 2 (1.4%)
Previous hospitalization within 3 months, n (%) 73 (52.5%)
Site of infection in 139 patients at enrollment, n (%)
 Lower respiratory tract infection 93 (66.9%)
 Blood stream infection 40 (28.8%)
 Urinary tract infection 18 (12.9%)
 Gastrointestinal tract infection 11 (7.9%)
 Skin and soft tissue infection 8 (5.8%)
 Surgical site infection 1 (0.7%)
 Bone and joint infection 1 (0.7%)
Documented bacteria-caused infections in 110 patients that required colistin therapy, n (%)
A. baumannii 79 (71.8%)
K. pneumoniae 18 (16.4%)
P. aeruginosa 9 (8.2%)
E. coli 2 (1.8%)
E. cloacae 2 (1.8%)
Medical procedure, n (%)
 Mechanical ventilation 117 (84.2%)
 Central venous catheterization 85 (61.2%)
 Chronic intermittent hemodialysis 53 (38.1%)
Severity of patient illness, mean ± SD
 APACHE II score at enrollment 21.8 ± 7.4
Antibiotic use for the current hospitalization prior to study enrollment, n (%) 134 (96.4%)
 Carbapenems 112 (80.6%)
 Cephalosporins 56 (40.3%)
 Beta-lactam/beta-lactamase inhibitors 75 (54.0%)
 Fluoroquinolones 39 (28.1%)
 Vancomycin 43 (30.9%)
 Aminoglycosides 6 (4.3%)
 Colistin 9 (6.8%)
Colistin use within 3 months prior to study enrollment, n (%) 15 (10.8%)